| M Margaret O'brien, MD | |
|
2451 Fillingim St, Pathology, Mobile, AL 36617-2238 | |
| (251) 471-7790 | |
| (251) 471-7715 |
| Full Name | M Margaret O'brien |
|---|---|
| Gender | Female |
| Speciality | Pathology - Anatomic Pathology & Clinical Pathology |
| Location | 2451 Fillingim St, Mobile, Alabama |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1992750863 | NPI | - | NPPES |
| 00120715 | Medicaid | MS | |
| 51510104 | Other | AL | BLUE CROSS |
| 51510105 | Other | AL | BLUE CROSS |
| 11-10215 | Other | AL | UNITED HEALTH CARE |
| 1165930 | Medicaid | LA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207ZP0102X | Pathology - Anatomic Pathology & Clinical Pathology | 18834 (Alabama) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| M Margaret O'brien, MD Po Box 40480, Mobile, AL 36640-0480 Ph: (251) 470-5842 | M Margaret O'brien, MD 2451 Fillingim St, Pathology, Mobile, AL 36617-2238 Ph: (251) 471-7790 |
News Archive
Steve Wonderlich, Chester Fritz Distinguished Professor of Clinical Neuroscience at the University School of Medicine and Health Sciences, North Dakota and Chair of Sanford's Eating Disorder Department, recently was awarded a National Institute of Mental Health (NIMH) grant to study a new treatment for binge eating disorder.
Synthetic Biologics, Inc., a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, today announced that enrollment has initiated and the first patient was dosed in a Phase 1b clinical trial of SYN-004, an investigational oral beta-lactamase enzyme for the prevention of Clostridium difficile (C. difficile) infection, antibiotic-associated diarrhea and secondary antibiotic-resistant infections in patients receiving intravenous (IV) beta-lactam antibiotic therapy.
Energy reduction is high on the agenda for many involved in food and health whether from the perspective of public health policy, dietary advice, product formulation and development, or making available food and drinks that people enjoy.
Primary results from a new clinical trial show that patients with type 1 diabetes treated with the monoclonal antibody teplizumab (MacroGenics, Inc.) exhibit greater preservation of C-peptide, a biomarker of islet cell function, compared to controls.
Houston Methodist researchers found that mice harboring human glioblastoma tumors in their brains had greatly enhanced survival and weight gain when given a newly developed prodrug.
› Verified 4 days ago
Dr. Lloyd Gardner, MD Pathology Medicare: Not Enrolled in Medicare Practice Location: 5 Mobile Infirmary Cir, Mobile, AL 36607 Phone: 251-460-0326 Fax: 251-460-2846 | |
Dr. Lee Fucich, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 5 Mobile Infirmary Cir, Mobile, AL 36607 Phone: 251-460-0326 Fax: 251-460-2846 | |
Elizabeth A. Manci, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 1700 Center St, Pathology, Mobile, AL 36604 Phone: 251-415-1612 Fax: 251-415-1003 | |
Carole Boudreaux, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 2451 Fillingim St, Pathology, Mobile, AL 36617 Phone: 251-471-7790 Fax: 251-471-7715 | |
Jonathan Newsom, Pathology Medicare: Medicare Enrolled Practice Location: 2451 University Hospital Dr, Mobile, AL 36617 Phone: 251-470-9912 | |
Dr. Rodney Edwin Shackelford, DO Pathology Medicare: Medicare Enrolled Practice Location: 2451 University Hospital Dr, Mobile, AL 36617 Phone: 251-471-7790 Fax: 251-471-7096 | |
Eugene Hart, M.D. Pathology Medicare: Not Enrolled in Medicare Practice Location: 2451 Fillingim St, Department Of Pathology, Mobile, AL 36617 Phone: 251-471-7026 |